November, 2007 - FIRST TIME IN YEARS THERE ARE LEGITIMATE REASONS TO OWN VODG.
1. A new facility is being constructed primarily to enable production. The previous facility was sufficient for R & D
biz.yahoo.com.
2. On August 20, 2007, the Company entered into a Consulting Agreement with Mr. Joe Nieusma of Superior Toxicology & Wellness ("Superior"). Under the terms of the agreement, Superior will provide services including, but not limited to:
o Assistance with the development and funding of the Company's current business plan;
o Assistance with the launch of products targeting applications in the development and discovery of new drug and biological products; and
o Assistance with the marketing and sales of all existing and proposed products and technology that are now available, or will be available for commercial distribution during the term of the agreement.
3. About Mr. Joe Nieusma
affygility.com.
4. A paragraph below from the companies executive summary
Notice names like Merck, GlaxoSmithKline, Roche, Lilly, Takeda, etc. Notice mention of Toxicology testing which ties in why Mr. Nieuma is on board
siliconinvestor.com.
Products for Research, Drug Development and Treatment of Animal Diabetes. While the market potential for a new human cell therapy of diabetes is enormous, the pathway to this market is long and costly. However, our plan also includes commercialization of derivative products targeting research, drug development/manufacturing and animal therapeutic markets prior to regulatory approval of a cell therapeutic product for treatment of human diabetes. A current target is the expansion of our present product line to include stem cell-derived human beta islets and related products. Human beta islet cells have substantial application to the development of new drugs both in safety and toxicology testing of all new drugs and also in the development of new drugs for treatment of diabetes. We intend to commercialize our stem cell-derived beta islets for such applications through sales of products, services and select non-exclusive licenses with those pharmaceutical firms engaged in such development, e.g., Merck, GlaxoSmithKline, Roche, Lilly, Takeda, etc. Another application of stem cell-derived beta islet cells is in the treatment of animal diabetes, which is also a significant health issue. Our initial target is cell therapy for diabetes in dogs and cats, but this may be expanded to include other species.
5. If a company like Merck or any major company uses VODG Beta islets it will be huge for VODG. If they make any kinds of progess in new drug research or diabetes research using these Islets its even bigger VODG already pr'd they are entering the revenue phase of their operations and building a bigger facility. He seems extremely confident besides revenues starting to flow earnings will follow because this is a high margin business.
"We believe that we have an opportunity to be the first company to market our targeted stem cell products into the niche market we have identified. Thus, we anticipate high margin sales and rapid capture of the target market that is quite substantial."
Dr. Musick has NOT diluted the shareholders, only 12MM outstanding with a float of about 5MM. THERE IS INCREDIBLE OPERATING LEVERAGE ON A PER SHARE BASIS!!! |
